Golden State Equity Partners Buys 20,000 Shares of Sangamo Therapeutics, Inc. $SGMO

Golden State Equity Partners raised its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 5.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 391,943 shares of the biopharmaceutical company’s stock after buying an additional 20,000 shares during the quarter. Golden State Equity Partners’ holdings in Sangamo Therapeutics were worth $212,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of SGMO. Jacobs Levy Equity Management Inc. increased its position in Sangamo Therapeutics by 74.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company’s stock valued at $851,000 after acquiring an additional 555,323 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Sangamo Therapeutics during the 4th quarter valued at about $353,000. Two Sigma Investments LP lifted its stake in shares of Sangamo Therapeutics by 222.1% in the 4th quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company’s stock worth $1,033,000 after purchasing an additional 698,296 shares during the period. Bank of America Corp DE lifted its stake in shares of Sangamo Therapeutics by 179.3% in the 4th quarter. Bank of America Corp DE now owns 331,256 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 212,638 shares during the period. Finally, GSA Capital Partners LLP boosted its holdings in shares of Sangamo Therapeutics by 2,962.2% in the first quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock worth $634,000 after buying an additional 934,649 shares during the last quarter. 56.92% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Stock Down 4.3%

SGMO opened at $0.53 on Wednesday. The company has a market capitalization of $159.09 million, a PE ratio of -1.82 and a beta of 1.20. The firm has a 50-day simple moving average of $0.53 and a two-hundred day simple moving average of $0.60. Sangamo Therapeutics, Inc. has a 52 week low of $0.41 and a 52 week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%.The firm had revenue of $18.31 million during the quarter, compared to the consensus estimate of $31.68 million. As a group, sell-side analysts expect that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on SGMO shares. Wall Street Zen raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday, September 4th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $4.50.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.